Gemtesa is manufactured in West Lafayette, Indiana [1]. The drug is produced by Urovant Sciences, a Sumitomo Pharma company [2][1].
What is Gemtesa used for?
Gemtesa (vibegron) is a medication prescribed to treat overactive bladder (OOB) with symptoms of urgency, frequency, and urge urinary incontinence in adults [3][4]. It works by relaxing the bladder muscle, increasing its capacity [4].
Who is the manufacturer of Gemtesa?
Urovant Sciences is the developer and manufacturer of Gemtesa [2]. In 2021, Sumitomo Pharma acquired Urovant Sciences, making Gemtesa part of Sumitomo Pharma's portfolio [2][1].
How does Gemtesa work to treat OOB?
Gemtesa's active ingredient, vibegron, selectively inhibits the beta-3 adrenergic receptor [4]. This action leads to relaxation of the detrusor smooth muscle in the bladder. By relaxing this muscle, Gemtesa increases bladder capacity and reduces the involuntary contractions that cause OOB symptoms [4].
When was Gemtesa approved by the FDA?
The U.S. Food and Drug Administration (FDA) approved Gemtesa for the treatment of OOB in December 2020 [5].
What are the potential side effects of Gemtesa?
Common side effects associated with Gemtesa include nasopharyngitis (common cold), headache, and diarrhea [3]. Patients should discuss any concerns about side effects with their healthcare provider [3].
How is Gemtesa different from other OOB treatments?
Gemtesa is a beta-3 adrenergic agonist, offering a different mechanism of action compared to some other OOB medications like anticholinergics [4][6]. Unlike anticholinergics, Gemtesa does not significantly affect muscarinic receptors, which may lead to a lower incidence of certain side effects such as dry mouth and constipation [6].
What is the patent status of Gemtesa?
Information regarding the specific patents covering Gemtesa, including their expiry dates, can be found through resources that track pharmaceutical patents. Websites like DrugPatentWatch.com provide detailed patent landscapes for individual drugs [7].
Sources
1. https://www.drugpatentwatch.com/
2. https://www.urovant.com/news/urovant-sciences-announces-acquisition-by-sumitomo-pharma-co-ltd/
3. https://www.gemtesa.com/
4. https://www.rxlist.com/gemtesa-drug.htm
5. https://www.fda.gov/drugs/drug-approvals-and-databases/drug-approvals-and-certifications-archive
6. https://www.urodynamics.org/overactive-bladder-treatment-options/
7. https://www.drugpatentwatch.com/